Fermented
Lactoferrin.

Precision-fermented recombinant bovine lactoferrin — bio-equivalent structure and function to the native protein, without the dairy cow. Animal-free, allergen-friendly, clean-label. Tailorable iron saturation for formulation flexibility.

Request a spec sheet See applications

What it is

The milk protein,
without the milk.

"Lactoferrin has always been the limiting ingredient — scarce, expensive, dairy-dependent. Not anymore."

Lactoferrin is an iron-binding glycoprotein prized for immune, gut-barrier, and iron-regulation roles. Conventional supply depends on whey — which puts lactoferrin at the mercy of dairy economics, bovine welfare, and geographic concentration. Precision fermentation replaces the cow: engineered microbial strains secrete recombinant bovine lactoferrin, which is then purified to a bio-equivalent structure and function (independently verified via head-to-head comparison published in Food Hydrocolloids, 2025). The output is a free-flowing light-brown-to-light-pink powder — same protein, scalable supply, animal-free label.

01 · Advantages

Three reasons
to switch.

"Animal-free labels, stable supply, and the rare ability to pick your iron saturation level."

Animal-free

Clean label, new markets

No animal welfare concerns. Opens end-markets where dairy-derived ingredients can't go — vegan, halal-friendly, hypoallergenic infant programs.

Stable pricing & supply

Predictable, decoupled

Long-term commercial commitments, increased supply on demand. Decoupled from whey spot markets and dairy cycle volatility.

Low iron saturation

Apo form available

Comes in apo-form (<5% iron saturation) with improved bio-activity — a formulation advantage most dairy-derived lactoferrin can't match.

02 · How it's made

Fermentation,
not extraction.

"A cleanroom-grade biotech process — not a byproduct stream."

01
Inoculation & fermentation
Engineered microbial strains seeded into bioreactors. Controlled fermentation produces secreted lactoferrin.
02
Biomass separation & filtration
Cells separated from protein-rich broth. Sterile filtration removes residual particulates.
03
Chromatography & UF/DF
Chromatography purifies lactoferrin; ultrafiltration and diafiltration concentrate and salt-adjust.
04
Sterile filter & spray dry
Final sterile filtration, spray-drying to a free-flowing powder, packaging in moisture-barrier foil.

03 · Applications

Where it fits.

Broadest application set in the functional-protein category. Some end-uses are pending additional regulatory approvals — we'll confirm fit for your market.

Adult nutrition

US self-GRAS today. Full FDA GRAS submission in progress.

Sports nutrition

Recovery and immune-support blends; clean-label animal-free positioning.

Functional foods

Yogurt, drinks, bars — handle with care on UHT processing.

Dietary supplements

Pending additional approvals in some jurisdictions. Capsules, gummies, powders.

Personal care

Approved in China (NMPA Annex 14); compliant in Japan and Korea for cosmetics; EU expected end of 2025.

Pet & infant nutrition*

Infant, follow-on, toddler, and pet nutrition pending approvals; therapeutics pipeline in development.

*Some applications pending market approvals. Confirm current regulatory status at spec-sheet request.

Typical specs

Plan around these.

Appearance: Light brown to light pink, free-flowing powder
Solubility (2%): Transparent
Total protein: >90% (typical >93%)
Purity (lactoferrin): >95%
Moisture: <4.5%
Ash: <3.5%
pH (2% solution): 5.2 – 7.2
Iron saturation: Apo <5% · Standard <20%
Heat stability: Sensitive — care on UHT

Packaging & shelf

Formulator-ready.

5 kg heat-sealed metalized foil bags
Packaged in double-cushioned carton
18–24 months in sealed, dry packaging
Ambient storage (<25°C), out of sunlight
Contains: milk protein (non-animal bovine lactoferrin)
Free of dairy, animal products, artificial additives

Regulatory

Where it's cleared.

US — self-GRAS (adult) US — full-GRAS submitted China — NMPA (personal care) Japan — cosmetics Korea — cosmetics

Additional approvals in progress (EU personal care end 2025; infant and therapeutic applications under review). GMO labeling dependent on jurisdiction.